GRI Bio (GRI) reported interim 6-week lung function results from its ongoing Phase 2a study evaluating GRI-0621 for the treatment of Idiopathic ...

In the second interim analysis, lung function was assessed from the first 24 subjects at 6 weeks. GRI-0621 treated patients demonstrated no worsening of forced vital capacity ("FVC”) at 6 weeks ...

Researchers have developed a method that combines AFM and AI to accurately profile macrophage mechanophenotypes.

Spectral Flow Cytometry Pioneer Unveils Innovations Accelerating Efficiency and DiscoveryFREMONT, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) - ...